Fresh analysis indicates that people who stop using popular slimming jabs like Mounjaro or Wegovy may regain shed pounds far faster than those who stop traditional lifestyle programs.
Research printed in a leading health publication shows that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"People using these medications should be cognizant of the potential of quick rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass within about 18 months.
Weighing Treatments
The study, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of the injectable medications with conventional dieting.
Scientists emphasize that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Experts believe the mechanism of the injections accounts for the heightened rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the therapy should be considered long-term.
This opinion is supported by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," comparing it to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the jabs explain a sudden return of hunger.
"It was like a switch flipping and you become starving," recalled one woman.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit modifications during treatment.
Widespread Interest
Figures indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and long-term success hinges on ongoing behavioural management.
